Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment

This Phase II interventional trial (n=60) aims to investigate whether psilocybin affects synaptic vesicular density (SVD) in individuals with amnestic Mild Cognitive Impairment (aMCI) compared to healthy participants.

Conducted by the Centre for Addiction and Mental Health, Canada, the study hypothesizes that psilocybin ingestion will lead to higher SVD levels in the brain, potentially associated with cognitive improvements.

Participants, aged 60 to 75, will be randomised to receive either two 25 mg doses of psilocybin or placebo separated by one week. Primary outcomes include measuring SVD using PET imaging and assessing cognition, while secondary outcomes involve examining memory and executive function. The study spans from November 2023 to July 2026, with contact details provided for study inquiries.

Topic Neurocognitive Disorders
Compound Placebo Psilocybin
Country Canada
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.